How a Study Became a Regulatory Benchmark – and Why the Ground Has Shifted
In 2006, FDA staff prepared a White Paper concerning potential adverse health risks associated with mercury in dental amalgam. The agency then brought the issue before a joint advisory panel in September 2006. The panel did not simply endorse the FDA staff’s conclusion. According to the contemporaneous record, the panel voted 13–7 against accepting the FDA staff’s safety conclusion.